GLP-1 Studio Podcast – Studio Special

Host: Amanda Bonello

On November 6th, 2025, the White House announced pricing agreements with Eli Lilly and Novo Nordisk that could reshape GLP-1 access for millions of Americans.

For the first time ever, Medicare and Medicaid will cover GLP-1 medications for obesity—with just a $50 copay. Brand name medications like Ozempic, Wegovy, and Zepbound are coming down to Most-Favored-Nation pricing, finally putting Americans on par with what other countries pay.

Discounted cash pay prices through TrumpRx are expected by the end of 2025. The full Medicare and Medicaid rollout is expected by April 2026.

For those who've been rationing doses, going without, or watching every door close—there is finally hope.

In this episode:

What the TrumpRx program means for pricing

How Most-Favored-Nation pricing works

What changes for Medicare, Medicaid, and commercial insurance

What this moment means after a year of advocacy

Resources:

Full pricing breakdown chart in the article below

Data sources: White House Fact Sheet (11/6/25), Eli Lilly & Co. press release (11/6/25), Novo Nordisk company announcement No. 32/2025

Connect with Amanda Bonello and the GLP-1 Studio Podcast: Learn more at GLP1Studio.com

Disclaimer: This content is for informational and advocacy purposes only. It reflects my personal understanding of recent policy announcements and publicly available information. I am not a medical professional or government representative. Always consult your healthcare provider for medical advice and check official sources for current policy and coverage details.

In this episode of the GLP-1 Studio Podcast, host Amanda Bonello sits down with Aja Beckett, founder of Shotsy, to talk about GLP-1 self-advocacy, personalized dosing, and the moment everything changes when food noise finally goes quiet.

Aja shares her personal GLP-1 journey, including navigating insurance barriers, prior authorizations, and paying hundreds of dollars a month just to access care. Together, Amanda and Aja unpack why obesity is a chronic disease, not a willpower problem, and why “eat less, move more” has failed so many people.

They also explore how tracking symptoms, side effects, and dosing patterns can empower patients to have better conversations with their doctors, especially when standard titration schedules don’t fit real bodies or real lives.

This conversation is about more than an app. It’s about dignity, access, and finally understanding that it’s not your fault.

Follow Aja:

- 🌐 Website- 📱 Instagram- 💻LinkedIn (Aja)- 💻LinkedIn (Shotsy)- 📱 TikTok

In This Episode, We Cover:

- Aja’s experience living with obesity, Hashimoto’s, and chronic inflammation- The reality of GLP-1 access, insurance denials, and high out-of-pocket costs- What “food noise” really is and what it feels like when it turns off- Why one-size-fits-all dosing doesn’t work for most patients- How tracking data can support self-advocacy with doctors and insurers- Navigating maintenance when there is little to no clinical guidance- Letting go of shame and reclaiming your right to care

Disclaimer: This episode is for educational and informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider regarding your health and treatment decisions.Learn more and listen here:

- 🎙️ GLP-1 Studio Podcast- 🎧 Spotify- 📱 Apple- 📖 SubStack- 💻 YouTube

In this episode of the GLP-1 Studio Podcast, host Amanda Bonello speaks with Caroline Colavita of BioCare Nutrition and Mario Testa of Robard Corporation about nutrition support for GLP-1 patients and the realities of modern weight loss care.

This conversation covers protein intake on GLP-1 medications, muscle preservation, body composition data, and how companies like BioCare and Robard are adapting clinical nutrition support for today’s GLP-1 and obesity-care landscape.

Topics discussed:

- Nutrition support for GLP-1 patients- Protein intake and muscle preservation during weight loss- Body composition scans and data-driven reassurance- Lead concerns in protein supplements and third-party testing- BioCare Nutrition’s patient-centered approach- Robard’s long history in clinical nutrition programs- Community and trust in GLP-1 care

The GLP-1 Studio Podcast focuses on patient education, lived experience, and vetted resources for people navigating GLP-1 medications and obesity care.

Disclosure:This interview and episode were not sponsored. Amanda Bonello is a BioCare affiliate and may earn a commission from qualifying purchases at no additional cost to listeners. BioCare separately compensated Amanda for a specific in-store video, which did not influence this episode or discussion.